Topline results were announced from a phase 3 trial evaluating Viaskin ® Peanut patch in peanut allergic children aged 4 to 7 years. Viaskin Peanut patch is an epicutaneous immunotherapy that delivers ...
After 12 months of treatment, more 4- to 7-year-olds with peanut allergy using the Viaskin Peanut patch vs. placebo were deemed treatment responders, according to data presented here. Additionally, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results